Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-28

Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients

Objective

Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.

Fields of science (EuroSciVoc)

Topic(s)

Call for proposal

FP7-PEOPLE-2012-IAPP
See other projects for this call

Funding Scheme

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
EU contribution
€ 390 695,04
Address
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (1)